.jpg)
Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said. It directly integrates with electronic health records (EHRs), billing systems, security and compliance platforms, clinical guidelines and workflows, coding, enterprise productivity platforms and Centers for Medicare & Medicaid Services (CMS) datasets.
U.S. hospitals lost an estimated $132.2 billion in net revenue to bad debt and final insurance denials in 2025, according to a Nov. 4 analysis from Kodiak Solutions. The analysis found that 2,400 hospitals and 375,000 physicians using the Kodiak platform lost $52.1 billion to bad debt and final insurance denials in 2025, up 17.6% from 2024. Extrapolating those findings to approximately 6,100 U.S. hospitals, Kodiak estimated nationwide revenue leakage of $132.2 billion.
The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist
The industry’s next major competitor may never build another national laboratory network or employ thousands of phlebotomists. It may simply own the device that notices something first. This should command the attention of every executive in diagnostics. The Apple Watch is not about to replace the clinical laboratory. The more interesting possibility is that companies such as Apple could capture something enormously valuable upstream: the moment when a consumer discovers there may be something worth testing. That changes the economics of diagnostics.
Trump administration announces $10B in awards for Rural Health Transformation Program’s second year
The Trump administration announced Monday funding for the second year of the Rural Health Transformation Program (RHTP), with $10 billion in awards slated for all 50 states. The U.S. Department of Health and Human Services (HHS) announced awards through the Centers for Medicare and Medicaid Services. Under the statute, half of the $10 billion-per-year distribution is split between the states evenly. The remaining half is determined by the CMS, with a portion of second-year funding being determined by states’ progress in implementing approved RHTP plans.
FDA orders new vision loss warning for GLP-1s
The FDA is requiring safety labeling changes for GLP-1 receptor agonists over a potential increased risk of a rare eye condition that can cause vision loss. The agency is requiring drugs including Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy to add information about non-arteritic anterior ischemic optic neuropathy, or NAION, to the warnings and precautions section of their labeling, according to a Nov. 9 drug safety communication. NAION can cause sudden, painless vision loss in one eye, which can be permanent.
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn